248 Sustained improvements in disease activity for up to two-years with ixekizumab in patients with active psoriatic arthritis who were either biologic-naïve or with previous inadequate response to tumour necrosis factor inhibitor therapy. (12th April 2019) - Jadon, Deepak R; Nassab, Mani Haschemi; Beneden, Katrien Van; Pum, Georg; Bradley, Andrew J